FDA REFORM THIRD-PARTY PROVISIONS WILL BE AMENDED TO PREVENT REVIEW "SHOPPING" -- HOUSE COUNSEL; AGENCY CONTINUES TO ATTACK "RADICAL" HOUSE BILL
FDA third-party review provisions will be amended in House legislation to alleviate concerns raised about direct negotiations between industry and outside reviewers, House Commerce Committee Counsel John Cohrssen indicated at a Food & Drug Law Institute meeting in Washington, D.C. May 13.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth